EP3035961A1 - Tollwutimpfstoff - Google Patents

Tollwutimpfstoff

Info

Publication number
EP3035961A1
EP3035961A1 EP14755333.3A EP14755333A EP3035961A1 EP 3035961 A1 EP3035961 A1 EP 3035961A1 EP 14755333 A EP14755333 A EP 14755333A EP 3035961 A1 EP3035961 A1 EP 3035961A1
Authority
EP
European Patent Office
Prior art keywords
sequence
mrna
utr
gene
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14755333.3A
Other languages
English (en)
French (fr)
Inventor
Margit SCHNEE
Thomas Kramps
Lothar Stitz
Benjamin Petsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curevac SE
Original Assignee
Curevac AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curevac AG filed Critical Curevac AG
Priority to EP18191308.8A priority Critical patent/EP3461498A1/de
Priority to EP14755333.3A priority patent/EP3035961A1/de
Priority to EP22151797.2A priority patent/EP4043032A1/de
Priority claimed from PCT/EP2014/002298 external-priority patent/WO2015024665A1/en
Publication of EP3035961A1 publication Critical patent/EP3035961A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP14755333.3A 2013-08-21 2014-08-21 Tollwutimpfstoff Withdrawn EP3035961A1 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP18191308.8A EP3461498A1 (de) 2013-08-21 2014-08-21 Tollwutimpfstoff
EP14755333.3A EP3035961A1 (de) 2013-08-21 2014-08-21 Tollwutimpfstoff
EP22151797.2A EP4043032A1 (de) 2013-08-21 2014-08-21 Tollwutimpfstoff

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2013002517 2013-08-21
EP14755333.3A EP3035961A1 (de) 2013-08-21 2014-08-21 Tollwutimpfstoff
PCT/EP2014/002298 WO2015024665A1 (en) 2013-08-21 2014-08-21 Rabies vaccine

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP18191308.8A Division EP3461498A1 (de) 2013-08-21 2014-08-21 Tollwutimpfstoff
EP22151797.2A Division EP4043032A1 (de) 2013-08-21 2014-08-21 Tollwutimpfstoff

Publications (1)

Publication Number Publication Date
EP3035961A1 true EP3035961A1 (de) 2016-06-29

Family

ID=56024445

Family Applications (3)

Application Number Title Priority Date Filing Date
EP22151797.2A Pending EP4043032A1 (de) 2013-08-21 2014-08-21 Tollwutimpfstoff
EP14755333.3A Withdrawn EP3035961A1 (de) 2013-08-21 2014-08-21 Tollwutimpfstoff
EP18191308.8A Withdrawn EP3461498A1 (de) 2013-08-21 2014-08-21 Tollwutimpfstoff

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP22151797.2A Pending EP4043032A1 (de) 2013-08-21 2014-08-21 Tollwutimpfstoff

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP18191308.8A Withdrawn EP3461498A1 (de) 2013-08-21 2014-08-21 Tollwutimpfstoff

Country Status (1)

Country Link
EP (3) EP4043032A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4035659A1 (de) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosome zur ausgabe von therapeutischen wirkstoffen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2575490A1 (en) * 2004-08-03 2006-02-16 Frank Notka Method for modulating gene expression by altering the cpg content
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
EP2955230A1 (de) 2010-07-30 2015-12-16 CureVac AG Komplexierung von nukleinsäuren mit disulfid-vernetzten kationischen komponenten zur transfektion und immunstimulation
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012116715A1 (en) * 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) * 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
RU2660565C2 (ru) 2012-03-27 2018-07-06 Кьюрвак Аг Молекулы искусственной нуклеиновой кислоты, содержащие 5'utr гена top

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMANN R ET AL: "A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein", JOURNAL OF VIROLOGY (ONLINE), AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 87, no. 3, 1 February 2013 (2013-02-01), pages 1618 - 1630, XP002753921, ISSN: 1098-5514, [retrieved on 20121121], DOI: 10.1128/JVI.02470-12 *
HILDEGUND C. J. ERTL ET AL: "Novel Vaccines to Human Rabies", PLOS NEGLECTED TROPICAL DISEASES, vol. 3, no. 9, 29 September 2009 (2009-09-29), US, pages e515, XP055450808, ISSN: 1935-2727, DOI: 10.1371/journal.pntd.0000515 *
See also references of WO2015024665A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4035659A1 (de) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosome zur ausgabe von therapeutischen wirkstoffen

Also Published As

Publication number Publication date
EP4043032A1 (de) 2022-08-17
EP3461498A1 (de) 2019-04-03

Similar Documents

Publication Publication Date Title
US11369694B2 (en) Rabies vaccine
US11965000B2 (en) Respiratory syncytial virus (RSV) vaccine
US20210401966A1 (en) Nucleic acid molecules and uses thereof
US20170326225A1 (en) Ebolavirus and marburgvirus vaccines
US20210162037A1 (en) Influenza mrna vaccines
EP3035960B1 (de) Impfstoff gegen das respiratorische synzytialvirus
EP4043032A1 (de) Tollwutimpfstoff

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151230

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: KRAMPS, THOMAS

Inventor name: PETSCH, BENJAMIN

Inventor name: STITZ, LOTHAR

Inventor name: SCHNEE, MARGIT

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170718

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20180911